Willy Noort
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Willy Noort has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dorien Pastoors
Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
1 shared publication - Duncan Brian
Stem Cell Group, UCL Cancer Institute, University College London, London, UK
1 shared publication - Eric M. Bindels
Department of Hematology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
1 shared publication - Jeroen A. A. Demmers
Proteomics Center, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication Julius Grasel
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany
1 shared publication- Leonie Smeenk
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 17 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (20) , eadk9076
Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2
Acute myeloid leukemia (AML) driven by the activation of EVI1 due to chromosome 3q26/ MECOM rearrangements is incurable. Because transcription factors such as EVI1 are notoriously hard to target, insight into the mechanism by which EVI1 drives myeloid transformation could provide alternative avenues for therapy. Applying protein folding predictions combined with proteomics technologies, we demonstrate that interaction of EVI1 with CTBP1 and CTBP2 via a single PLDLS motif is indispensable for leukemic transformation. A 4× PLDLS repeat construct outcompetes binding of EVI1 to CTBP1 and CTBP2 and inhibits proliferation of 3q26/ MECOM rearranged AML in vitro and in xenotransplant models. This proof-of-concept study opens the possibility to target one of the most incurable forms of AML with specific EVI1-CTBP inhibitors. This has important implications for other tumor types with aberrant expression of EVI1 and for cancers transformed by different CTBP-dependent oncogenic transcription factors.
- 17 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (20) , eadk9076
Open AccessOncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2
Acute myeloid leukemia (AML) driven by the activation of EVI1 due to chromosome 3q26/ MECOM rearrangements is incurable. Because transcription factors such as EVI1 are notoriously hard to target, insight into the mechanism by which EVI1 drives myeloid transformation could provide alternative avenues for therapy. Applying protein folding predictions combined with proteomics technologies, we demonstrate that interaction of EVI1 with CTBP1 and CTBP2 via a single PLDLS motif is indispensable for leukemic transformation. A 4× PLDLS repeat construct outcompetes binding of EVI1 to CTBP1 and CTBP2 and inhibits proliferation of 3q26/ MECOM rearranged AML in vitro and in xenotransplant models. This proof-of-concept study opens the possibility to target one of the most incurable forms of AML with specific EVI1-CTBP inhibitors. This has important implications for other tumor types with aberrant expression of EVI1 and for cancers transformed by different CTBP-dependent oncogenic transcription factors.